FDA digs into semaglutide CV benefits, eye safety ahead of Novo Nordisk drug's panel review
admin 16th October 2017 Uncategorised 0It’s not often that a drug company alerts the media to FDA review documents filed ahead of an agency advisory panel hearing. But Novo Nordisk did just that Monday as its key GLP-1 drug semaglutide, a follow-up to blockbuster Victoza, preps for its close-up before agency experts.
More: FDA digs into semaglutide CV benefits, eye safety ahead of Novo Nordisk drug's panel review
Source: fierce